{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:58:14Z","timestamp":1773932294486,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313601"],"award-info":[{"award-number":["2017A030313601"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012976","name":"Saint Mary's University","doi-asserted-by":"publisher","award":["2016A020215112"],"award-info":[{"award-number":["2016A020215112"]}],"id":[{"id":"10.13039\/100012976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC82170163"],"award-info":[{"award-number":["NSFC82170163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970147"],"award-info":[{"award-number":["81970147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770170"],"award-info":[{"award-number":["81770170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.leukres.2025.108155","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:47:05Z","timestamp":1765957625000},"page":"108155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Frequency and prognostic significance of RAS pathway alterations in adult acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"160","author":[{"given":"Jiawang","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10230","key":"10.1016\/j.leukres.2025.108155_bib1","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet (Lond. Engl. )"},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11684-020-0821-6","article-title":"Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia","volume":"15","author":"Li","year":"2021","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.leukres.2025.108155_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148972","article-title":"Genome-wide DNA copy number analysis of acute lymphoblastic leukemia identifies new genetic markers associated with clinical outcome","volume":"11","author":"Forero-Castro","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.leukres.2025.108155_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/tp-22-683","article-title":"Analysis of RAS gene mutations in adverse events during first induction chemotherapy in childhood acute lymphoblastic leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Pedia"},{"issue":"2","key":"10.1016\/j.leukres.2025.108155_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2017.152","article-title":"Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia","volume":"117","author":"Forero-Castro","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2025.108155_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-05681-4","article-title":"Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia","author":"Ou","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.108155_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fonc.2014.00160","article-title":"Ras\/Raf\/MEK\/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting","volume":"4","author":"Knight","year":"2014","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108155_bib8","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.2020.269431","article-title":"Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia","volume":"107","author":"Kaburagi","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/sj.leu.2403272","article-title":"RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia","volume":"18","author":"Perentesis","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/leu.2017.303","article-title":"RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"32","author":"Jerchel","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2025.108155_bib12","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.leukres.2025.108155_bib13","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1608420113","article-title":"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia","volume":"113","author":"Oshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.leukres.2025.108155_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14474","article-title":"Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics","volume":"176","author":"Tasian","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108155_bib15","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/pbc.25683","article-title":"Analysis of KRAS and NRAS gene mutations in Arab Asian children with acute leukemia: high frequency of RAS mutations in acute lymphoblastic leukemia","volume":"62","author":"LaFY","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2025.108155_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2025.108155_bib17","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2013.847934","article-title":"Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil","volume":"55","author":"Barbosa","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28899","article-title":"RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions","volume":"68","author":"Huang","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3265","article-title":"The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group","volume":"42","author":"Li","year":"2024","journal-title":"Hematol. Oncol."},{"issue":"7380","key":"10.1016\/j.leukres.2025.108155_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2025.108155_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation-2014.1.174","article-title":"The genomic landscape of acute lymphoblastic leukemia in children and young adults","volume":"2014","author":"Mullighan","year":"2014","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib23","first-page":"207","article-title":"NRAS mutations in de novo acute leukemia: prevalence and clinical significance","volume":"51","author":"Dunna","year":"2014","journal-title":"Indian J. Biochem Biophys."},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cam4.2757","article-title":"RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD","volume":"9","author":"Sakhdari","year":"2019","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.leukres.2025.108155_bib25","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41409-022-01797-1","article-title":"Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia","volume":"57","author":"Tang","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2025.108155_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353118","article-title":"Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition","volume":"141","author":"Simons","year":"2013","journal-title":"Cytogenet. Genome Res."},{"issue":"9","key":"10.1016\/j.leukres.2025.108155_bib27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.108155_bib28","article-title":"Ras pathway mutation feature in the same individuals at diagnosis and relapse of childhood acute lymphoblastic leukemia","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Pedia"},{"issue":"2","key":"10.1016\/j.leukres.2025.108155_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10428194.2023.2278026","article-title":"Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen","volume":"65","author":"Ou","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib30","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1002\/cam4.5196","article-title":"TNFAIP3 mutation is an independent poor overall survival factor for patients with T-cell acute lymphoblastic leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41375-021-01460-6","article-title":"Outcomes in adolescent and young adult patients (16\u201330 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232","volume":"36","author":"Burke","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.108155_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2018.03.001","article-title":"RAS-mediated oncogenic signaling pathways in human malignancies","volume":"54","author":"Khan","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108155_bib33","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2005-03-0867","article-title":"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years","volume":"106","author":"Bowen","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108155_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.3099","article-title":"Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome","volume":"41","author":"Ren","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108155_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.leukres.2025.108155_bib36","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108155_bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/leu.2017.303","article-title":"RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"32","author":"Jerchel","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2025.108155_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155893","article-title":"MEK inhibition sensitizes precursor B-cell acute lymphoblastic leukemia (B-ALL) cells to dexamethasone through modulation of mTOR activity and stimulation of autophagy","volume":"11","author":"Polak","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.leukres.2025.108155_bib39","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3324\/haematol.2017.185975","article-title":"Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM","volume":"104","author":"Matheson","year":"2019","journal-title":"Haematologica"},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.108155_bib40","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1182\/blood-2023-185855","article-title":"The MEK inhibitor selumetinib in combination with dexamethasone leads to responses in adult and pediatric patients with relapsed RAS-pathway mutated acute lymphoblastic leukemia: results of a phase 1\/2 study","volume":"142","author":"Vormoor","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108155_bib41","unstructured":"Princess Maxima Center for Pediatric Oncol, et al. International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children \u2013 Sub-protocol D Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies ( \u3008https:\/\/eudract.ema.europa.eu\/\u3009)."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:28:21Z","timestamp":1773923301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"alternative-id":["S0145212625006459"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108155","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and prognostic significance of RAS pathway alterations in adult acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108155"}}